XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC – XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia.… CISION PRNewswireMarch 5, 2025
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC – XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia.… CISION PRNewswireMarch 5, 2025
Press ReleaseNew TXOne Networks OT/ICS Cybersecurity Report Details Growing Range of Risks Facing Companies as Digital Transformation Unfolds Globally Supply-chain vulnerabilities, aging infrastructure, patching difficulties and gaps in incident response demand urgent… CISION PRNewswireMarch 5, 2025
Global Terrorism Index 2025: Terrorism Spreads as Lone Wolf Attacks Dominate the West LONDON, March 5, 2025 /PRNewswire/ — The number of countries recording a… CISION PRNewswireMarch 5, 2025
Kuaishou's MSCI ESG Rating Upgraded to "A," Highlighting Outstanding Achievements in Sustainable Development HONG KONG, March 5, 2025 /PRNewswire/ — Kuaishou Technology ("Kuaishou" or the "Company";… CISION PRNewswireMarch 5, 2025
Press ReleaseInterSystems Unveils IntelliCare: A Next-Generation, AI-Powered Electronic Health Record BANGKOK, March 5, 2025 /PRNewswire/ — InterSystems, a creative data technology provider… CISION PRNewswireMarch 5, 2025
Press ReleasePantai Hospital Kuala Lumpur and IMU University Sign MoU to Advance Medical Research and Education KUALA LUMPUR, Malaysia, March 5, 2025 /PRNewswire/ — Pantai Hospital Kuala Lumpur… CISION PRNewswireMarch 5, 2025
BusinessPress ReleaseAxiom Partners with Know Your Customer to Elevate Business KYC Standards in the Digital Asset Market SINGAPORE, March 5, 2025 /PRNewswire/ — Axiom announces its partnership with Know… CISION PRNewswireMarch 5, 2025
